news

  • 31 January 2017
    Registration of Document E pertaining to the planned strategic combination between Genticel and Genkyotex

    Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developing innovative immunotherapies, and Genkyotex, a privately-held Swiss biopharmaceutical company and the leader in NOX therapies, today announce that the information document (Document E) drawn up in relation to the planned strategic combination between the two companies announced on December 22, 2016 was registered with the French financial market authority (Autorité des Marchés Financiers - AMF) under reference number E.17-004 on January 31, 2017.

    The planned contribution transaction remains subject to the approval of Genticel’s shareholders at the general meeting scheduled for February 28, 2017, being specified that the main shareholders of Genticel, representing, together with certain employees and executives, a total of 51% of the share capital and voting rights of Genticel, have undertaken to vote in favor of the transaction.

    Admission to trading on the regulated markets of Euronext in Paris and Brussels of the new Genticelshares issued to Genkyotex’s shareholders in remuneration of their contributed shares will be requested as soon as the contribution transaction is implemented. These new shares will be fully fungible with existing Genticel shares.

    In view of the admission to trading of the new shares on the regulated market of Euronext in Brussels, the document E registered with the AMF today will be submitted to the Belgian Financial Services and Markets Authority (FSMA) in order for the latter to make an equivalence decision. This planned combination between Genticel and Genkyotex would create a European group with a pipeline of first-in-class NOX inhibitors in fibrosis and inflammatory pain.